Search research articles
Contact Us
Filters
Showing results (51-60 of 53) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 53 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
A L Hamilton, J P Eder, A C Pavlick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R Hui, E B Garon, J W Goldman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 1, 1997
High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes
C Wheeler, C Eickhoff, A Elias, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 53) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 53 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
A L Hamilton, J P Eder, A C Pavlick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R Hui, E B Garon, J W Goldman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 1, 1997
High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes
C Wheeler, C Eickhoff, A Elias, et al.
Page
of 6